These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8213795)

  • 1. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection.
    Frenken LA; van Lier HJ; Jordans JG; Leunissen KM; van Leusen R; Verstappen VM; Koene RA
    Am J Kidney Dis; 1993 Oct; 22(4):553-6. PubMed ID: 8213795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the efficacy of measures to reduce pain after subcutaneous administration of epoetin alfa.
    Frenken LA; van Lier HJ; Koene RA
    Nephrol Dial Transplant; 1994; 9(9):1295-8. PubMed ID: 7816293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.
    Veys N; Dhondt A; Lameire N
    Clin Nephrol; 1998 Jan; 49(1):41-4. PubMed ID: 9491285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen in hemodialysis patients.
    St Peter WL; Lewis MJ; Macres MG
    Am J Kidney Dis; 1998 Sep; 32(3):470-4. PubMed ID: 9740164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers.
    Berthoux F; Ryckelynck JP; Rouanet S; Gelu-Mantoulet S; Montestruc F; Mouchel P; Choukroun G;
    Clin Nephrol; 2008 Jul; 70(1):33-40. PubMed ID: 18793546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin.
    Veys N; Vanholder R; Lameire N
    Am J Nephrol; 1992; 12(1-2):68-72. PubMed ID: 1415368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study.
    Granolleras C; Leskopf W; Shaldon S; Fourcade J
    Clin Nephrol; 1991 Dec; 36(6):294-8. PubMed ID: 1769141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
    Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
    Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.
    Halstenson CE; Macres M; Katz SA; Schnieders JR; Watanabe M; Sobota JT; Abraham PA
    Clin Pharmacol Ther; 1991 Dec; 50(6):702-12. PubMed ID: 1752115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.
    Togawa A; Tanaka T; Nagashima S; Keta H; Kobayashi Y; Nishikawa Y; Yanai M; Tanaka H
    Br J Clin Pharmacol; 2004 Sep; 58(3):269-76. PubMed ID: 15327586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
    Paganini EP; Eschbach JW; Lazarus JM; Van Stone JC; Gimenez LF; Graber SE; Egrie JC; Okamoto DM; Goodkin DA
    Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immediate pain sensation is less with subcutaneous epoietin-beta compared to subcutaneous darbepoietin-alpha.
    Ter Wee PM; de Koter Y; van der Veer O; van Vliet MH
    Clin Nephrol; 2009 Sep; 72(3):177-80. PubMed ID: 19761721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help?
    Morris KP; Hughes C; Hardy SP; Matthews JN; Coulthard MG
    Nephrol Dial Transplant; 1994; 9(9):1299-301. PubMed ID: 7816294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
    Haag-Weber M; Eckardt KU; Hörl WH; Roger SD; Vetter A; Roth K
    Clin Nephrol; 2012 Jan; 77(1):8-17. PubMed ID: 22185963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.